search
Back to results

The Effectiveness and Safety of Gabapentin for Post-operative Pain After Cesarean Section

Primary Purpose

Pain

Status
Terminated
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Gabapentin
lactose
Sponsored by
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pain focused on measuring Cesarean section, Gabapentin

Eligibility Criteria

18 Years - 50 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Women undergoing elective cesarean delivery

Exclusion Criteria:

  • Patients unable to communicate in English
  • Patients with an American Society of Anesthesiologists (ASA) classification of 3 or higher
  • Patients with contraindications to any of the medications used in the study
  • Patients with contraindications to spinal anesthesia
  • Patients who have taken any pain medication in the past week
  • Patients with fetuses having congenital abnormalities
  • Patients with severe mental disorders
  • Patients with HIV or hepatitis infections
  • Intravenous drug users
  • Patients with uncontrolled hypertension and diabetes
  • Patients with central nervous system tumours

Sites / Locations

  • Mount Sinai Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

1

2

Arm Description

Gabapentin

Placebo

Outcomes

Primary Outcome Measures

Pain score by visual analogue scale (VAS) on movement at 24 hours postoperatively.

Secondary Outcome Measures

Pain at rest and on movement by VAS at 4, 12, 24 & 48 hours postoperatively.
Opioid consumption at 4, 12, 24 & 48 hours postoperatively.
Assessment of sedation, pruritis, nausea, vomiting and dizziness on a 4-point scale (absent, mild, moderate, severe) and document treatment if required.
Time to first maternal request for supplemental analgesia.
Presence of pain 3 months postoperatively.
Neonatal information: Apgar scores, arterial cord blood gases, arterial and venous cord blood gabapentin concentration, need for NICU admission
Neonatal pain response at vitamin K injection (0-100%)
Maternal gabapentin levels (25 patients)

Full Information

First Posted
December 12, 2007
Last Updated
July 29, 2009
Sponsor
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT00573664
Brief Title
The Effectiveness and Safety of Gabapentin for Post-operative Pain After Cesarean Section
Official Title
The Effectiveness and Safety of Gabapentin for Post-operative Pain After Cesarean Section: A Randomized Placebo-controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
July 2009
Overall Recruitment Status
Terminated
Why Stopped
Interim analysis showed a significant reduction in the pain scores
Study Start Date
November 2007 (undefined)
Primary Completion Date
November 2008 (Actual)
Study Completion Date
February 2009 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Samuel Lunenfeld Research Institute, Mount Sinai Hospital

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to determine whether a single dose of gabapentin, given before cesarean section, will reduce pain in the initial 24 hours after surgery. Gabapentin has been very effective at treating pain after knee and hip operations, hysterectomies, and many other types of surgeries. We believe that it may be effective for treating pain after cesarean sections, but it has never been studied for this purpose.
Detailed Description
A cesarean section is a surgical procedure and, like all surgeries, there is pain after the operation. The purpose of this study is to find out if patients have less pain after a cesarean delivery when they receive a single dose of a gabapentin before the surgery. We are also interested in whether or not the dose of gabapentin reduces the need for other pain-killing medication during this time. Patients will be randomly assigned to receive either gabapentin or a placebo. In addition, all patients will receive the usual standard of care and medication for pain (intrathecal morphine,oral paracetamol and diclofenac). At 4, 12, 24 and 48 hours after the operation, patients will be asked about their pain and satisfaction with pain management. The dose of gabapentin given is thought to be safe for the baby, and we plan to investigate whether the gabapentin has any effect on the baby's pain response when given his/her vitamin K injection. Gabapentin has also been shown to reduce long-term pain that can develop, and patients will be followed up at 6 weeks to be asked about their pain at that time.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain
Keywords
Cesarean section, Gabapentin

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
46 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Active Comparator
Arm Description
Gabapentin
Arm Title
2
Arm Type
Placebo Comparator
Arm Description
Placebo
Intervention Type
Drug
Intervention Name(s)
Gabapentin
Other Intervention Name(s)
Neurontin
Intervention Description
single oral dose of 600mg gabapentin
Intervention Type
Other
Intervention Name(s)
lactose
Intervention Description
Single dose
Primary Outcome Measure Information:
Title
Pain score by visual analogue scale (VAS) on movement at 24 hours postoperatively.
Time Frame
24 hours
Secondary Outcome Measure Information:
Title
Pain at rest and on movement by VAS at 4, 12, 24 & 48 hours postoperatively.
Time Frame
48
Title
Opioid consumption at 4, 12, 24 & 48 hours postoperatively.
Time Frame
48
Title
Assessment of sedation, pruritis, nausea, vomiting and dizziness on a 4-point scale (absent, mild, moderate, severe) and document treatment if required.
Time Frame
48 hours
Title
Time to first maternal request for supplemental analgesia.
Time Frame
48 hours
Title
Presence of pain 3 months postoperatively.
Time Frame
3 months
Title
Neonatal information: Apgar scores, arterial cord blood gases, arterial and venous cord blood gabapentin concentration, need for NICU admission
Time Frame
48 hours
Title
Neonatal pain response at vitamin K injection (0-100%)
Time Frame
1 hour
Title
Maternal gabapentin levels (25 patients)
Time Frame
6 months (samples will be stored and sent together)

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Women undergoing elective cesarean delivery Exclusion Criteria: Patients unable to communicate in English Patients with an American Society of Anesthesiologists (ASA) classification of 3 or higher Patients with contraindications to any of the medications used in the study Patients with contraindications to spinal anesthesia Patients who have taken any pain medication in the past week Patients with fetuses having congenital abnormalities Patients with severe mental disorders Patients with HIV or hepatitis infections Intravenous drug users Patients with uncontrolled hypertension and diabetes Patients with central nervous system tumours
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jose CA Carvalho, MD
Organizational Affiliation
MOUNT SINAI HOSPITAL
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mount Sinai Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 1X5
Country
Canada

12. IPD Sharing Statement

Learn more about this trial

The Effectiveness and Safety of Gabapentin for Post-operative Pain After Cesarean Section

We'll reach out to this number within 24 hrs